This study was undertaken to identify a new combined plant extract (PAC) intended to treat in patients with acne vulgaris. We detected strong antibacterial activities of Pinus densiflora leaf extract (LP) against Propionibacterium acnes (P. acnes) and Staphylococcus epidermidis (S. epidermidis) and anti-inflammatory effect of Artemisia annua L. extract (AA). To develop more effective agents in multiple targeting of the physiopathology of acne, a combination of three plant extracts (PAC), Pinus densiflora leaf extract (LP), Artemisia annua L. extract (AA), and Citrus junos fruit juice (FC), indicated anti-proliferative effect on P. acnes-induced HaCaT cells proliferation, was prepared mixing at ratio 2:1:1. PAC with MIC values of 2.25 mg/ml and 0.75 mg/ml against P. acnes and S. epidermidis was more active than LP (2.50 mg/ml and 1.00 mg/ml), was the most active of three extracts. PAC also showed more effective anti-inflammatory activity than a single plant extract in P. acnes-treated NF, HaCaT cells and LPS-treated Raw 264.7 cells. And then, we evaluated sebosuppressive effect of PAC on differentiation and lipogenesis of sebocytes. Results showed that PAC reduced sebum production and IGF-1-stimulated proliferation on sebocytes. In addition, PAC (final 2%) applied in a test product clinically decreased skin oil content, sebum output level, and the number of closed comedones and open comedones in a period of 4 weeks. The results of the studies demonstrate that PAC is clinically effective with anti-bacterial, anti-inflammatory, sebum protective properties for acne prone skin. These results suggest that in patients with acne, PAC can provide adjunctive care by targeting pathological factors including bacterial proliferation, inflammation and sebum production.
Introduction
Acne vulgaris is a multifactorial skin disease, and its pathogenesis includes increased sebum production (seborrhea), hyperkeratosis, proliferation of Propionibacterium acnes (P. acnes) and inflammation [1] [2] [3] .
In particular, sebum overproduction is a major concurrent event in the development of acne lesions [4] [5] because sebum serves as a nutrient source for P. acnes, activating toll-like receptors TLR2 and TLR4, leading to the release of proinflammatory cytokines/chemokines such as interleukin-1α (IL-1α), IL-6, IL-8, tumor necrosis factor-α (TNF-α), and adhesion molecule like intercellular adhesion molecule-1 (ICAM-1) [6] [7] [8] . It can also promote hyperkeratinization, resulting from abnormal keratinization of infundibular epithelium [9] .
Therefore, acne treatment relies on developing new drugs that regulate sebum excretion centers [10] [11] .
Sebum is a lipid-rich fluid that is, secreted by the sebaceous gland, and it is composed of cholesterol, fatty acids, fatty alcohols, di-and tri-glycerides, wax esters, sterol esters and squalene [12] [13] [14] . It has long been known that sebum excretion in sebocytes is regulated by androgens and androgen-mediated stimulation of the sebaceous gland changes sebum composition [15] [16] [17] [18]. Moreover, subsequent excess in sebum production of androgen-stimulated sebocytes and follicular keratinocytes causes hyperkeratosis, which results in blockage of the follicle in sebaceous glands and aggravates acne vulgaris. In normal hair follicles, keratinocytes are carried by sebum flow to the skin surface, but these are densely packed, and their proliferation rate increases in an acne lesion [19] [20] .
Recent evidence suggests that IGF-1 levels increase in people with clinical acne and IGF-1 or insulin, which can stimulate sebaceous gland lipogenesis in rat sebocytes [21] [22] [23] . Thus, studies are increasingly carried out to target the suppression of IGF-1-induced lipogenesis in sebocytes. Epigallocatechin-3-Gallate (EGCG), the major polyphenol in green tea, suppresses sebum production on IGF-1-stimulated SZ95 sebocytes by inhibiting PI3K-Akt-mTORC1 (Phosphoinositide 3-kinase-Akt-mammalian target of rapamycin complex 1) signaling [24] [25] .
Due to the pathophysiology of acne caused by the increase in sebum secretion, hyperkeratosis, growth of P. acnes, and inflammation, there are limits to developing safe, effective therapeutics for acne. Even the most effective treatments require several months to produce noticeable effects since therapeutic agents that are currently available to treat acne target different physiological aspects, such as killing bacteria, preventing inflammation or suppressing comedo production.
Therefore, developing novel agents for acne, by targeting a diverse range of pathological factors is of particular importance, and there has been an increase in interest for multifunctional ingredients, indicating antibacterial activity, anti-inflammation, sebo-suppressive effect, and hyperkeratosis.
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Pinus thunbergii is a tree species that is extensively planted along coastal regions in Korea, China, and Japan. This species is demanding since it is salt-tolerant, stabilize dunes, and provides a wind-break effect [26] [27] [28] .
Pinus thunbergii extracts have been shown to have antiviral activity against influenza virus A/PR/8/34 and, inhibitory effects on antigen-induced degranulation in RBL-2H3 cells [29] [30] . Currently, there has been little to no study of the bioactivity of Pinus thunbergii, and in the study, we have thus evaluated the activity of Pinus thunbergii leaf extracts in treating acne.
Artemisia annua L., belongs to the Asteraceae family and, is one of the most widely used herbs in oriental medicine. It is also well known as the source of sesquiterpene lactone artemisinin, which is used to treat chloroquine-resistant and cerebral malaria [31] 
Methods

Materials
Dulbecco's-Modified Eagle's Medium (DMEM), antibiotics, fetal bovine serum (FBS) and phosphate-buffered saline (PBS) and trypsin were purchased from Gibco (USA). Lipopolysaccharides (LPS) and Griess reagent were obtained from Sigma Aldrich (St. Louis, MO, USA).
Preparation of Extracts
Leaves of Pinus thunbergii, Artemisia annua L., and fruits of Citrus junos Tana respectively to obtain the mixture preparation, PAC.
Bacterial Culture
P. acnes strain (ATCC 11827) and S. epidermidis (ATCC 12228) were obtained from the Korean Collection for Type Cultures (KCTC, Korea). P. acnes was cultured in BHI (brain heart infusion) broth medium for 24 h at 37˚C under anaerobic conditions. S. epidermidis was cultured in nutrient broth (NB) in aerobic conditions at 37˚C for 24 h.
Cell Culture
The 
Minimum Inhibitory Concentration (MIC) Test
Bacteria were pre-cultured anaerobically for 24 h at 37˚C. About 1 × 10 4 cells from the pre-culture were seeded into 3 ml of broth medium and were cultured until their exponential phase had been reached. Subsequently, the extracts were treated into the culture broth. After bacterial incubation at 37˚C under anaerobic conditions for 24 h, the MIC of the extracts were determined using a two-fold serial dilution method. The lowest concentration yielding no bacterial growth was regarded as the MIC value.
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Griess Assay
The Raw 264.7 cells were seeded at 1 × 10 5 cells/well into a 24 well-tissue culture plate and incubated overnight. The cells were pretreated with LP, AA, FC, and PAC for 1 h and were further incubated with LPS (200 ng/ml) for 24 h at 37˚C.
Then, the amount of NO production was measured by performing a Griess assay [43] . The culture supernatants were incubated with Griess reagent (0.1% N-1-naphthylenediamine digydrochloride and 1% sulphanilamide in 5% phosphoric acid) for 30 min at RT. The absorbance at 570 nm was measured using a spectrometer, and the nitrate concentration was calculated from a NaNO 2 standard curve.
IL-8 ELISA Assay
The NF cells (5 × 10 3 cells/well) in serum-free medium were pretreated with LP, AA, FC, and PAC for 1 h and stimulated with P. acnes (1:1000) for 48 h at 37˚C.
Then, the culture supernatants were harvested for IL-8. The IL-8 concentration resulting from its production was measured by using a commercially available ELISA kit (eBioscience, USA), and the absorbance at 405 nm was measured using a spectrometer. The IL-8 concentration was determined using a standard curve.
Cell Viability Assay
The Raw264.7, NF, and HaCaT cells assayed in terms of viability using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT), which is reduced to purple formazan in living cells. The cells were plated in triplicate wells of 24 well-tissue culture plates and were incubated for 24 h. The cells were then exposed to LP, AA, FC, and PAC for 24 h at 37˚C. The MTT solution (1 mg/ml) was then added to each well and was cultured for 2 h. Subsequently, the supernatant was removed, and the insoluble purple formazan was dissolved in dimethyl sulfoxide (DMSO, St. Louis, MO, USA). The absorbance at 540 nm was measured using a spectrophotometer.
Cell Cycle Analysis
To measure the cell cycle progression, a flow cytometric analysis was performed with propidium iodide (PI). The SEB-1 sebocytes were treated with 1 ug/ml PAC or 1 uM EGCG treatments and then, the cells were stimulated with 20 nM of IGF-1 in DMEM without serum for 24 h. After that, the cells were pelleted, 
Nile Red Staining
The SEB-1 sebocytes were treated with 20 nM of IGF-1 with 1 ug/ml PAC or 1 uM EGCG treatments for 24 h. The cells were harvested and washed with phosphate-buffered saline without Ca 2+ and Mg 2+ . The harvested cells were fixed with 4% paraformaldehyde for 15 min, and then stained with 1 ug/ml Nile red (Sigma, St Louis, MO) solution for 5 min while protected from light at 37˚C. An observation was realized using a fluorescence microscope with appropriate filters.
Clinical Study
The efficacy and tolerability of PAC-containing test product in treating facial acne has also been clinically validated. PAC-containing test product and a control product were formulated as shown in Table 1 
Human Skin Primary Irritation Test
A patch test was performed to evaluate the irritation potential of PAC on human skin. The subject group included 31 healthy females who had no history of allergenic contact dermatitis, and the average age of subjects was 41.6 ± 6.5 yrs (ranged 20 -50). The PAC (2%) formulated with squalene was prepared and applied to healthy skin on the back. The patch test system was usually removed after 48 hours. Once the patches were removed, a reading was performed after 48 and 72 h. The readings were rated according to the modification of Frosch and Kligman [44] as well as the Cosmetic, Toiletry and Fragrance Association (CTFA) guidelines as follows: 0 = no reaction; 1 = slight erythema, spotty of diffuse; 2 = moderate uniform erythema; 3 = intense erythema with oedema: 4 = intense erythema with oedema and vesicles. The subjects were instructed to keep the test sites dry during the application period. This study was approved by the ethics committee of the DERMAPRO/Skin Research Center.
Statistical Analysis
Statistical significance of the data was analysed using one-way ANOVA analysis and Student's t-test. All experiments were repeated at least three times. A P value < 0.05 was considered to be significant.
Results
Anti-Bacterial Effect of LP, AA, and PAC against P. acnes and S. epidermidis
The anti-bacterial activity of LP, AA, FC, and PAC against P. acnes and S. epidermidis was investigated by measuring the minimum inhibitory concentration (MIC). The MIC was determined using a two-fold serial dilution (Table 2) . Then, tetracyclin and erythromycin were employed as positive controls. LP, AA, and PAC were founded to have significant inhibitory effects against both bacteria. Among three tested single extracts, LP exhibited the strongest activity with MIC values of 1 mg/ml and 2.5 mg/ml against S. epidermidis and P. acnes, respectivly. However, PAC inhibited the growth of S. epidermidis and P. acnes at the lower concentration of 0.75 mg/ml and 2.25 mg/ml, although its activity was less potent than those of tetracyclin and erythromycin. The results showed that PAC has stronger anti-bacterial ability than a single extract against S. epidermidis and P. acnes.
Anti-Inflammatory Effect of LP, AA, and PAC on P. acnes or LPS-Induced Inflammation
The increase in the inflammatory response within the pilosebaceous unit through bacteria colonization of the follicule is another critical pathological 
Anti-Proliferative Effects of FC and PAC on Human Keratinocytes
As shown in Figure 1 These results exhibited PAC has inhibitory effect on P. acnes-mediated HaCaT cells proliferation.
Protective Effect of PAC on Sebocyte Differtiation
An excess in sebum production is a major concurrent event associated with the pathogenesis of acne. To identify whether PAC has a sebosuppressive effect, we examined the effect of PAC on lipid production and proliferation in human sebocytes. Recent studies have shown that elevated insulin/insulin-like growth factor-1 (IGF-1) signaling stimulates the androgen metabolism of sebocytes and the lipogenesis of sebaceous glands [21] [23]. We investigated the effect of PAC on sebocyte proliferation and lipid production in IGF-1-stimualted SEB-1 cells. The results are presented as mean ± standard deviation (SD) (n = 3). *P < 0.05 vs. control. **P < 0.05 vs. P. acnes-stimulated, extract nontreated group.
After the sebocytes were treated with 20 nM of IGF-1, PAC of 1 ug/ml was treated for 24 h, and the harvested cells were analyzed by the cell cycle analysis. As shown in Figure 4 (a), the result indicates that PAC (67.87%) decreases the proliferation of SEB-1 cells by arresting the cell cycle progression of a level comparable with 73.94% of EGCG, is employed as positive control [24] [25] (Figure 3(a) ).
Suppressive Effect of PAC on Sebocyte Lipogenesis
An excess in sebum secretion is one of multiple factors that are associated with the pathogenesis of acne and regulating lipid production on sebocytes also has a crucial role in acne treatment. Therefore, PAC was examined to determine whether it has an effect on the lipogenesis of sebocytes upon IGF-1-induced sebum secretion with EGCG as a positive control. Treatment with IGF-1 resulted in an increase in sebum secretion, which was suppressed by treatment with PAC, as observed with nile red staining (Figure 3(b) ). The results suggest that PAC can reduce the rate of sebum excretion stimulated by IGF-1 and can regulate sebum production in acne lesions. 
Clinical Effect of PAC-Containg Test Product on Acne Prone Skin
To investigate the efficacy of PAC-containing test product versus a control product, the test and control product were applied twice a day for a 4-weeks on 20 volunteers. The skin oil content (μg/ml), number of skin sebum, numbers of non-inflammatory and inflammatory acne lesion was measured before treatment, at 2 weeks and 4 weeks following 4 consecutive weeks treatment of test product. The results showed a significant decrease in skin oil content of 48.9% after 4 weeks and sebum secretion rate of 17.6% after 2 weeks (Figure 4(a) , Figure 4(b) ). Compared to before treatment, the number of whiteheads and blackheads were significantly reduced at PAC-containg test product group at 2 weeks and 4 weeks (Figure 4 (c), Figure 4(d) ). In addition, compared to the control product group at 4 weeks, PAC-containg test product group significant reduction of 27.2% and 11.3% in the mean number of whiteheads and blackheads. Papules and pustules were showed a tendency to decrease at 4 weeks in PAC-containing test product group compared to the control product group (Table 3) . These results indicate that the PAC complex exerts an acne-mitigating effect.
Human Skin Primary Irritation Test of PAC
A skin primary irritation test in humans was conducted to evaluate the irritation potential of PAC on human skin. A human patch test is a general method that is used to determine the human skin safety of a substance for clinical applications.
The patch test was usually removed after 48 hours, and readings were recorded 30 minutes after removing the strips (day 2) and after 24 (day 3) or 48 (day 4) hours, as modified by Frosch & Kligman [44] . 31 healthy volunteers aged 20 to 50 years (average 41.6 ± 6.5 yrs) were recruited for this study. During this study, none of the 31 subjects experienced a reaction based on the 48-and 72-h readings (Table 4 ) and PAC did not induce any skin reaction. Therefore, these data demonstrate that the PAC is within the scope of the slight-irritation and is safe to apply to human skin.
Discussions
Acne is characterized by multifactorial conditions, including hormonal imbalance, abnormal ductal keratinization, bacterial overgrowth, inflammation, and excessive sebum production. Despite the existence of many studies on the pathophysiological mechanisms of acne, the development of effective ingredients for treatment has been limited because such substances have shown a single effect among multiple physiological factors of acne, not on multiple aspects [47] [48]. Recently, there has been an increasing focus on developing therapeutic agents that target multiple pathogenesis of acne, with no side effects. Pretsch et al. reported that Talaromyces wortmannii extracts have an anti-microbial activity against acne-inducing bacteria including P. acnes and anti-inflammatory properties by inhibiting P. acnes-mediated activation of NF-kB and activator protein-1 (AP-1) activation, as well as IL-8 release [49] . Results from in vitro, ex vivo, and clinical studies on BGM complex composed of bakuchiol, Ginkgo biloba extract, mannitol for acne therapy showed antibacterial activity against ±  1+  2+  3+  4+  ±  1+  2+  3+ 4+ 48 h 72 h Mean   1 Squalene  ----------0  0  0   2 PAC(2%) ----------0  0  0 P. acne, antioxidation activity of squalene, anti-inflammatory activity and regulation of sebum composition [50] .
In the current study, we first report on the antibacterial activity against P. acnes of Pinus thunbergii needle extract, Artemisia annua L. extract, and Citrus junos Tanaka fruit juice and anti-inflammatory activity of Pinus thunbergii needles extract and Artemisia annua L. extract.
We also assessed antibacterial properties against P. acnes and S. epidermidis, anti-inflammatory potential of a new combined plant extract (PAC), consisting of Pinus thunbergii needle extract, Artemisia annua L. extract, and Citrus junos Tanaka fruit juice. PAC showed the lowest MIC value of 2.25 mg/ml and 0.75 mg/ml against P. acnes and S. epidermidis and was more effective than LP and AA on inhibition of P. acnes-and LPS-stimulated inflammation. In addition, we evaluated sebosupressive and clinical effect on acne prone skin of PAC whether PAC can regulate multiple pathogenic factor of acne. The results indicated that PAC had suppressive effect on differentiation and lipogenesis in IGF-1-stimulated SEB-1 cells. In clinical study, compared to the control product group at 4 weeks, skin oil content, skin sebum number, and the numbers of whiteheads and blackheads in PAC-containg test product group were significantly decreased. Furthermore, a patch test was performed to confirm the safety of PAC, and it did not show any adverse reactions on human skin.
Based on these results, this study suggests that PAC may be introduced as a potential therapeutic agent for acne vulgaris.
Conclusion
In summary, our results reveal that PAC is effective in suppressing multifactorial pathological conditions of acne, including antimicrobial activities against and S. epidermidis, anti-inflammatory activities, sebo-suppressive effects, and reduction of skin oil content, sebum number, and the numbers of acne lesions. Therefore, this study demonstrated that the PAC can improve acne treatment and can be provided as an effective new agent for acne therapy.
